Plain-English translation of NCT06800313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called HLD-0915 (also known as JNJ-101556143) to see if it can help treat advanced prostate cancer, particularly in men whose cancer has continued to grow despite previous therapies. The study is being run in phases—first to find the right dose and form of the medication that works best and is safest, then to test it more broadly in different groups of prostate cancer patients. Researchers want to learn whether this medication can slow or stop cancer growth and improve outcomes for men at different stages of the disease.
Many men with metastatic prostate cancer eventually stop responding to current standard treatments, and their cancer continues to grow. This medication is being studied because early research suggests it may work through a different mechanism and could help patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify for this trial, you would take the study medication orally in treatment cycles lasting 21 days each. You would continue taking the medication as long as your cancer is not progressing and you are tolerating the treatment well, or until you decide to stop or your doctor recommends stopping due to side effects or other medical reasons. Throughout the study, you would have regular visits for blood tests, imaging scans, and check-ins with the research team to monitor how the medication is working and track any side effects.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States